ING1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line. This product features targeted disruption of the ING1 tumor suppressor gene, creating a loss-of-function model suitable for investigating the molecular mechanisms of tumor suppression and oncogenic signaling. The polyclonal nature of the knockout population provides a heterogeneous genetic background that can mimic tumor heterogeneity, making it a versatile tool for functional genomics and drug discovery applications. This gene-edited cell product enables robust interrogation of ING1-dependent pathways without the clonal artifacts associated with single-cell-derived knockouts.
The host cell line, A-549, is a widely used model of non-small cell lung cancer (NSCLC), originating from the alveolar basal epithelial cells of a 58-year-old male patient. These cells exhibit an adherent epithelial morphology and harbor wild-type KRAS and TP53 genes, representing a genetic context distinct from many other NSCLC lines that carry KRAS mutations. A-549 cells are commonly employed to study lung adenocarcinoma biology, including proliferation, invasion, and response to chemotherapeutic agents. Their wild-type p53 status makes them particularly valuable for examining p53-dependent signaling networks, as the intact p53 pathway allows for clear assessment of modulatory inputs from tumor suppressors such as ING1.
ING1 functions as a type II tumor suppressor that integrates stress signals with chromatin remodeling and p53-mediated transcription. Mechanistically, ING1 interacts directly with TP53 through its plant homeodomain (PHD) finger and forms complexes with histone acetyltransferases like EP300 and CREBBP, as well as histone deacetylases such as HDAC1 and SIN3A. Upon cellular stress or DNA damage, ING1 is stabilized and enhances p53 transcriptional activity, leading to increased expression of the cyclin-dependent kinase inhibitor CDKN1A (p21) and the pro-apoptotic factor BAX, while repressing anti-apoptotic BCL2 and proliferation markers like CCND1. Conversely, ING1 activity is regulated by upstream signals including DNA damage, which can be induced by HDAC inhibitors that further modulate the epigenetic landscape. ING1 also interacts with PCNA to coordinate DNA replication with repair, highlighting its role in maintaining genomic stability.
In the A-549 cellular context, knockout of ING1 provides a powerful system to dissect the interplay between ING1 loss and p53 functionality in lung adenocarcinoma. Given that ING1 is frequently downregulated or mislocalized in NSCLC and other cancers, this polyclonal knockout model allows researchers to recapitulate the loss-of-heterozygosity events observed in patient tumors. The wild-type p53 background of A-549 cells ensures that any observed phenotypic changes??such as altered cell cycle profiles, resistance to apoptosis, or modified drug sensitivity??can be directly attributed to ING1 deficiency without confounding p53 mutations. This makes the model especially relevant for probing how ING1 status influences responses to DNA-damaging chemotherapeutics or targeted agents that modulate the p53 pathway.
This polyclonal knockout cell product is ideally suited for a range of research applications, including the elucidation of ING1-p53 interaction dynamics via co-immunoprecipitation and immunofluorescence, transcriptomic profiling through RNA-seq and RT-qPCR, and functional assays for apoptosis (Annexin V staining), cell cycle (flow cytometry), and drug sensitivity (viability/IC50 assays). Researchers can employ luciferase reporter assays to measure p53 transcriptional output and ChIP-qPCR to assess ING1-dependent chromatin engagement. By providing a genetically disrupted ING1 background, these cells enable systematic investigation of tumor suppressor networks and pathways influencing chemosensitivity in lung adenocarcinoma. For more information, please contact Ascent Research to discuss your experimental requirements.
